Skip to Content

Soliqua 100/33 Dosage

Generic name: insulin glargine 100U in 1mL, lixisenatide 33ug in 1mL
Dosage form: injection, solution

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Important Dosage Information

The following are important dosing information for SOLIQUA 100/33, a combination of insulin glargine and lixisenatide:

  • Discontinue therapy with lixisenatide or basal insulin prior to initiation of SOLIQUA 100/33.
  • In patients inadequately controlled on less than 30 units of basal insulin or on lixisenatide, the recommended starting dosage of SOLIQUA 100/33 is 15 units (15 units insulin glargine/5 mcg lixisenatide) given subcutaneously once daily.
  • In patients inadequately controlled on 30 to 60 units of basal insulin, the recommended starting dosage of SOLIQUA 100/33 is 30 units (30 units insulin glargine/10 mcg lixisenatide) given subcutaneously once daily.
  • Administer SOLIQUA 100/33 subcutaneously once a day within the hour prior to the first meal of the day.
  • The maximum dosage of SOLIQUA 100/33 is 60 units (60 units insulin glargine/20 mcg lixisenatide) [see Warnings and Precautions (5.5)].
  • The SOLIQUA 100/33 Pen delivers doses from 15 to 60 units in a single injection (see Table 1) [see Dosage and Administration (2.2)].
  • Use alternative antidiabetic products if patients require a SOLIQUA 100/33 daily dosage:
    below 15 units, or
    over 60 units

Table 1 presents the units insulin glargine and the micrograms of lixisenatide in each dosage of SOLIQUA 100/33.

Table 1: Units of Insulin Glargine and Micrograms of Lixisenatide in Each Dosage of SOLIQUA 100/33
SOLIQUA 100/33
(dose window display)*
Insulin glargine component dose Lixisenatide component dose Comment
*
The dose window on the SOLIQUA 100/33 pen displays numbers for the even units and displays lines for the odd units.
2 --- --- Safety test dose – not for injection
15 15 units 5 mcg Recommended starting dosage for patients previously treated with lixisenatide or less than 30 units of basal insulin
16 16 units 5.3 mcg
17 17 units 5.7 mcg  
18 18 units 6 mcg  
19 19 units 6.3 mcg  
20 20 units 6.7 mcg  
21 21 units 7 mcg  
22 22 units 7.3 mcg  
23 23 units 7.7 mcg  
24 24 units 8 mcg  
25 25 units 8.3 mcg  
26 26 units 8.7 mcg  
27 27 units 9 mcg  
28 28 units 9.3 mcg  
29 29 units 9.7 mcg  
30 30 units 10 mcg Recommended starting dosage for patients previously treated with 30 to 60 units of basal insulin
31 31 units 10.3 mcg
32 32 units 10.7 mcg  
33 33 units 11 mcg  
34 34 units 11.3 mcg  
35 35 units 11.7 mcg  
36 36 units 12 mcg  
37 37 units 12.3 mcg  
38 38 units 12.7 mcg  
39 39 units 13 mcg  
40 40 units 13.3 mcg  
41 41 units 13.7 mcg  
42 42 units 14 mcg  
43 43 units 14.3 mcg  
44 44 units 14.7 mcg  
45 45 units 15 mcg  
46 46 units 15.3 mcg  
47 47 units 15.7 mcg  
48 48 units 16 mcg  
49 49 units 16.3 mcg  
50 50 units 16.7 mcg  
51 51 units 17 mcg  
52 52 units 17.3 mcg  
53 53 units 17.7 mcg  
54 54 units 18 mcg  
55 55 units 18.3 mcg  
56 56 units 18.7 mcg  
57 57 units 19 mcg  
58 58 units 19.3 mcg  
59 59 units 19.7 mcg  
60 60 units 20 mcg Maximum daily dosage [see Warnings and Precautions (5.5)]

Titration of SOLIQUA 100/33

  • After starting with the recommended dosage of SOLIQUA 100/33, based upon prior insulin dose or lixisenatide use [see Dosage and Administration 2.1], titrate the dosage upwards or downwards by two to four units (see Table 2) every week based on the patient's metabolic needs, blood glucose monitoring results, and glycemic control goal until the desired fasting plasma glucose is achieved. The dosage of SOLIQUA 100/33 is between 15 to 60 units (see Table 1).
  • To minimize the risk of hypoglycemia or hyperglycemia, additional titration may be needed with changes in physical activity, meal patterns (i.e., macronutrient content or timing of food intake), or renal or hepatic function; during acute illness; or when used with other medications [see Warnings and Precautions (5.4) and Drug Interactions (7)].
Table 2: Recommended Titration of SOLIQUA 100/33 (Every Week)*
Self-Monitored Fasting Plasma Glucose SOLIQUA 100/33 Dosage Adjustment
*
The recommended SOLIQUA 100/33 dosage is between 15 to 60 units (see Table 1)
Above target range +2 units (2 units of insulin glargine and 0.66 mcg of lixisenatide) to +4 units (4 units insulin glargine and 1.32 mcg lixisenatide)
Within target range 0 units
Below target range -2 units (2 units of insulin glargine and 0.66 mcg of lixisenatide) to -4 units (4 units of insulin glargine and 1.32 mcg lixisenatide)

Missed Doses

Instruct patients who miss a dose of SOLIQUA 100/33 to resume the once-daily regimen as prescribed with the next scheduled dose. Do not administer an extra dose or increase the dose to make up for the missed dose.

Important Administration Instructions

  • The SOLIQUA 100/33 prefilled pen is for single-patient use only [see Warnings and Precautions (5.3)].
  • Train patients on proper use and injection technique before initiating SOLIQUA 100/33.
  • Always check the SOLIQUA 100/33 label before administration [see Warnings and Precautions (5.5)]
  • Visually inspect for particulate matter and discoloration prior to administration. Only use SOLIQUA 100/33 if the solution is clear and colorless to almost colorless.
  • Inject SOLIQUA 100/33 subcutaneously into the abdominal area, thigh, or upper arm.
  • Rotate injection sites within the same region from one injection to the next to reduce the risk of lipodystrophy [see Adverse Reactions (6.1)].
  • Do not administer intravenously, intramuscularly, or via an insulin pump.
  • Do not dilute or mix SOLIQUA 100/33 with any other insulin or solution.
  • Do not split the dose of SOLIQUA 100/33.

More about Soliqua (insulin glargine / lixisenatide)

Consumer resources

Professional resources

Related treatment guides

Hide